Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are major causes of morbidity and mortality worldwide. Their development and progression are influenced by environmental exposures, such as cigarette smoking and air pollution, as well as genetic susceptibility. Despite advances in disease management, early diagnosis, accurate differential diagnosis, personalized treatment, and continuous monitoring remain significant clinical challenges. This project aims to improve the management of inflammatory lung diseases through the development and validation of innovative diagnostic, monitoring, and therapeutic approaches. The study will identify and validate multi-omics biomarkers for the differential diagnosis and prognosis of COPD, IPF, and related respiratory diseases, using machine learning techniques to develop diagnostic and prognostic biochips. Environmental determinants, including indoor and outdoor exposome factors, will be assessed to better understand their contribution to pulmonary inflammation and disease progression. The project will also develop nanotechnology-based therapeutic formulations combined with precision inhalation devices and integrate a telemedicine platform for real-time monitoring of clinical and environmental data, enabling the early detection of exacerbations and supporting personalized disease management. The expected outcomes include improved diagnostic accuracy, enhanced risk stratification, personalized therapeutic strategies, reduced disease exacerbations, and improved quality of life for patients with inflammatory lung diseases.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Innate immunity
Timeframe: Baseline to Month 27
Adaptive immunity in blood
Timeframe: baseline to month 27
Extracellular matrix proteins from saliva and serum
Timeframe: baseline to month 27
serum microRNAs
Timeframe: baseline to month 27
Genetic polymorphisms
Timeframe: baseline to month 27
Salivary Raman spectral fingerprint
Timeframe: baseline to month 27
Forced Expiratory Volume in 1 second
Timeframe: baseline to month 27
VC
Timeframe: baseline to month 27
Total Lung Capacity
Timeframe: baseline to month 27
Inspiratory Capacity
Timeframe: baseline to month 27
Expiratory Reserve Volume
Timeframe: baseline to month 27
Residual Volume
Timeframe: baseline to month 27
Diffusing Capacity of the Lung for Carbon Monoxide / Alveolar Volume
Timeframe: baseline to month 27
Blood gas analysis - PaO2
Timeframe: baseline to month 27
Blood gas analysis - PaCO2
Timeframe: baseline to month 27
Test 6 minute walk
Timeframe: baseline to month 27